αvβ6 is one member of the αv integrin subfamily (αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8) that is expressed in the lungs, kidneys, and skin (
1,
7,
8,
10). αvβ6 is one of the integrins known to be distributed in epithelial cells and is upregulated after injury or inflammation (
1). The function of αvβ6 is through the activation of transforming growth factor β (TGF-β) by binding the latency-associated peptide (
18). Transgenic mice deficient in integrin αvβ6 provide a useful tool to study lung phenotypes in animal experiments. Although β6 deletion induces hyperinflammation in the lungs in the basal state, the deletion of β6 protects against bleomycin-induced lung edema (
19) and fibrosis (
18), acute lung injury induced by lipopolysaccharide (LPS) instillation (
19), and acute lung injury induced by high-tidal-volume ventilation (
11).
Finally, deletion of β6 causes the development of emphysema that is associated with induced secretion of MMP-12 from macrophages and the development of larger macrophages in the lungs of knockout mice (
17). The enlargement of macrophages suggests that the macrophages are activated and that innate immunity may be perturbed in lungs. αvβ6 integrin appears to play an important role in the modulation of the inflammatory response associated with several experimental models of lung injury, and we hypothesized that blockade of this integrin might also improve lung injury induced by
Pseudomonas aeruginosa. Furthermore, if blocking αvβ6 integrin is not protective against
P. aeruginosa pneumonia, it would be critical to demonstrate that this new treatment does not increase the vulnerability of the patients to nosocomial bacteria, such as
P. aeruginosa, since this bacterium invariably colonizes the distal airways of patients with acute lung injury and is now the most common gram-negative bacterium responsible for the development of nosocomial pneumonia in mechanically ventilated patients (
5).
β6 integrin deletion protects by suppressing TGF-β activation in the lung (
2,
24,
25). TGF-β has been shown to increase endothelial (
9) and epithelial permeability (
19), decrease ENaC expression in the apical membrane of alveolar type II cells, and increase alveolar flooding (
3). In LPS-induced lung injury experiments in mice, blockade of TGF-β with a soluble chimeric TGF-β type II receptor (rsTGF-βRII-Fc) led to protective results similar to those seen in mice missing the β6 gene (
19). Overexpression of TGF-β increases apoptosis of airway epithelial cells and increases lung fibrosis induced by bleomycin (
14), while blocking TGF-β reduced lung injury induced by LPS intratracheal instillation (
19). These studies suggest that TGF-β plays an important role in inducing lung injury, and blockade of TGF-β has been considered as a therapy for patients with acute lung injury. Anti-inflammatory therapies, including corticosteroids and anti-tumor necrosis factor alpha (anti-TNF-α), have increased host vulnerability to infection (
15,
16). Therefore, these studies were done to determine the effect of a blockade of TGF-β on bacterium-induced lung injury.
MATERIALS AND METHODS
Mice and genotyping.
Mice were housed in an air-filtered, temperature-controlled (24°C), pathogen-free barrier with free access to food and water. Room humidity was controlled between 35 and 40%. Littermate wild-type mice (FVB/NJ, originally from Jackson Laboratories, body weight of ca. 22 to 26 g) and αvβ6 knockout mice (FVB/NJ background, 6 to 8 weeks old, body weight of ca. 21 to 25 g) were used in the present study. As done previously (
19), all of the mice were confirmed with genotyping at day 5. The primers used for genotyping were 5′-CAGTAAATCGTTGTCAACAG-3′ (P1), 5′-AACCCTTGCAGGTAAGTGAG-3′ (P2), and 5′-TCTTCTGTCACGTCCTCTGA-3′ (P3). P1 is paired with P3 for targeted alleles, and P2 is paired with P3 for wild-type alleles. This study was approved by Institute of Animal and Use Committee at University of California, San Francisco.
Material and regents.
αvβ6 antibody and control immunoglobulin G (IgG; 1 and 3 mg/kg, given intraperitoneally [i.p.] 16 h before bacterial challenge) were obtained from Biogen Idec (
26). rsTGF-βRII-Fc (2 mg/kg, given i.p. 24 h before bacterial challenge) was also obtained from Biogen Idec (
19). Enzyme-linked immunosorbent assay (ELISA) kits for mouse (KC, interleukin-10 [IL-10], TNF-α, and macrophage inflammatory protein 2 [MIP-2]) were purchased from R&D (Minneapolis, MN).
Bacterial culture and preparation.
P. aeruginosa strains PA103 and PAK were used in the present study. PA103 is a standard lab strain, and PAK was obtained as a gift from Stephen Lory. PA103 is a nonmucoid strain that secretes the potent type III cytotoxin, ExoU, while PAK secretes the less-virulent ExoS cytotoxin. Both strains were cultured in duplicate in MINS medium overnight, washed twice, and resuspended in sterile Ringer lactate solution to a concentration of 109 CFU/ml. The P. aeruginosa suspension was diluted further with sterile phosphate-buffered saline (PBS) to obtain a final concentration of 2 × 107 CFU/ml or 1 × 108 CFU/ml in PBS.
Bacterial administration and lung injury measurement in mice.
Mice were anesthetized with Avertin (250 mg/kg, i.p.). The skin around the neck area was sterilized with betadine and cut open to expose the jugular vein. A 0.1-ml portion of PBS (containing 0.1 μCi of
125I-labeled albumin) was injected into the jugular vein, and then the skin was closed with 5-0 sutures. The mouse was laid on a board with its head elevated at 45°. Then, 50 μl of PBS (containing 1 × 10
6 CFU of PA103 or 5 × 10
6 CFU of PAK) was instilled into the left lung through the trachea via the mouth by using a 27G gavage needle (
23). The mouse was allowed to recover for 15 min prior to replacement into the cage. Mice were active and appeared normal after 30 min. At 4 or 8 h after the bacterial instillation, a rectal temperature was recorded prior to euthanization with a larger dose of Avertin (500 mg/kg, i.p.). Blood samples were collected in a sterile fashion by using right ventricle punctures after thoracotomies had been done. The mouse lungs were removed, weighed, and homogenized for lung injury measurements. Excess lung water, endothelial permeability, and extravascular plasma equivalents were calculated as previously described (
5). Radioactivity per gram of blood and lung was measured by using a gamma counter (Packard Instrument Company, Meriden, CT). For survival studies, 5 × 10
6 CFU of PAK was instilled into each mouse. Body weights and core temperatures were recorded at 1, 2, 3, 4, and 8 h. The time of death of each mouse was recorded.
BAL.
Bronchoalveolar lavage fluid (BAL) was collected by infusing 1.5 ml of sterile PBS (containing 5 mM EDTA) into the lungs of the mice after tracheal cannulation. Gentle suction was applied, and ca. 85% of the fluid was withdrawn from the lungs. The collected fluid was centrifuged at 1,000 rpm for 10 min. The supernatant was stored immediately at −80°C for protein concentration and for cytokine measurements. The pellet was resuspended in 100 μl of PBS for cytocentrifuge preparation after hemolysis of the red blood cells; hemolysis was achieved by adding hypotonic PBS (200 mosmol for 20 s). The total BAL cell number was obtained by using a Beckman Coulter (Coulter Corp., Miami, FL), and the cells were analyzed after hematoxylin and eosin staining of the cytospun material. Blood neutrophils were counted by using a Hemavet (Drew Scientific, Inc., Oxford, CT).
Bacterial cultures from the lungs, spleen, and blood.
Mouse blood, the spleen, and lungs were collected in a sterile fashion. The lungs and spleen were homogenized in sterile containers, and the homogenates were serially diluted and plated in triplicate on sheep blood agar plates. Blood was collected in sterile tubes containing 10% sodium citrate prior to serial dilution and plating in triplicate on sheep blood agar plates for bacterial colony counts.
In vitro macrophage isolation, culture, and quantification of bacterial phagocytosis.
Alveolar macrophages were isolated by using a published protocol with some modifications (
4). Briefly, the mouse lungs were lavaged with 1.5 ml of PBS (containing 5 mM EDTA) and centrifuged at 1,000 rpm for 10 min. The supernatants were discarded, and the pellets were resuspended in Dulbecco modified Eagle culture medium. A total of 2 × 10
5 cells were plated in 96-well plates, followed by incubation for 1 h. Trypan blue staining demonstrated 97% cell viability, and morphological analysis documented that more than 95% of the cells attached to the bottom of the wells were macrophages. After incubation for 1 h, the culture medium was replaced, and the same strain of
P. aeruginosa utilized in the animal experiments, PA103, was added to each well (bacteria/cell ratio of 50:1), followed by incubation at 37°C for 1 h. The supernatant was then discarded, and macrophages were washed five times with sterile PBS. Macrophages were examined under microscopy (×60 oil). Phagocytosis by the macrophages was measured by counting the number of bacteria inside the macrophages. Approximately 100 macrophages from each group of mice were examined to quantify phagocytosis.
Pretreatment with β6 integrin blocking antibody.
To determine the acute effects of β6 blockade, wild-type mice were pretreated with anti-αvβ6 blocking antibody, 3G9 (1 and 3 mg/kg, same dose for control antibody) 16 h prior to bacterial challenge (
26). The dosages used were the same as the doses that had produced significant protection in experiments utilizing bleomycin and radiation (
6,
20). Mice were then anesthetized and treated as they had been in the lung injury experiments (see above).
Pretreatment with murine rsTGF-βRII-Fc.
Wild-type mice were pretreated with rsTGF-βRII-Fc (2 mg/kg, i.p.) or with control IgG (2 mg/kg, i.p.) 24 h before bacterial challenge, and lung injury was measured according to the protocol used for the β6 antibody experiments.
BAL and plasma cytokine measurement.
BAL and plasma were collected as described above. BAL was diluted five times, and plasma was diluted two times for concentration measurements. ELISAs were carried out with MIP-2, KC (i.e., neutrophil chemotactic protein), TNF-α, and IL-10 kits (R&D) according to the manufacturer's protocol.
Statistical analysis.
A Student t test was used for statistical analysis, and a P value of <0.05 was considered significant.
DISCUSSION
The main finding of this study is that integrin β6 deletion or antibody blockade of TGF-β did not increase the susceptibility of the host to
P. aeruginosa pneumonia, nor do these interventions protect mice from
P. aeruginosa-induced lung injury. The role of αvβ6 integrin in lung injury and/or fibrosis has been investigated using β6-null mice and by acutely blocking αvβ6 with an antibody. Deletion of the β6 gene protected against lung injury induced by bleomycin, LPS, and high tidal volume ventilation (
11,
18,
19). Why then was β6 gene deletion not protective against lung injury induced by live
P. aeruginosa? First, live bacteria cause lung injury through several mechanisms that cannot be replicated by the instillation of endotoxin alone (
20), and LPS does not lead to the same degree of lung injury as seen with live bacteria (
13). Therefore, LPS-induced lung injury is not a good surrogate for infection-induced lung injury.
It appears that more bacteria were eliminated in the lungs of the β6-null mice, since significantly fewer bacteria were cultured in the lungs of the β6-null mice after 4 h. The increased killing might have occurred because of the increased number of inflammatory cells, including macrophages and neutrophils, in the lungs of these mice. We could not demonstrate that phagocytosis by the β6-null macrophages was superior or inferior to that of the wild-type macrophages. However, the presence of these inflammatory cells may have also led to increased lung injury in the infected β6-null mice. KC and MIP-2 are two potent chemoattractant chemokines that recruit neutrophils into the alveolar spaces in mice (
21). Cytokine concentration measurements from the BAL documented elevated basal KC BAL concentrations in the β6-null mice compared to levels in the BAL from wild-type mice, which may help explain why more neutrophils were in the lungs at baseline in the β6-null mice. BAL IL-10 concentrations in the β6-null mice were lower than in the BAL from the wild-type mice before and after the
P. aeruginosa instillations, which may also explain why there were more neutrophils in the lungs of the β6-null mice given the nature of IL-10 as an anti-inflammatory cytokine. We have found that recombinant IL-10 pretreatment improved oxygenation and hemodynamics, decreased bacteremia, and improved survival in rabbits instilled with the same
P. aeruginosa strain, PA103, that was utilized in the present experiments (
22). Therefore, the decreased IL-10 levels in the β6-null mice may also explain why these animals did not have an improved outcome with this infection. The TNF-α and MIP-2 plasma levels were comparable between the wild-type and β6-null mice before and after bacteria challenge. However, there were more inflammatory cells, elevated KC concentrations, decreased IL-10 concentrations, and increased numbers of neutrophils in the blood of the β6-null animals; all of these factors may have contributed to the lack of protection against lung injury after
P. aeruginosa instillation in the β6-null mice.
TGF-β is an important factor involved in extracellular matrix deposition and tissue repair after the acute phase of lung injury. TGF-β suppresses the activation of macrophages in the alveolar space under normal conditions and is also involved in inflammatory response upon various insults. Integrin αvβ6 has been shown to bind and activate TGF-β (
18). TGF-β has three isoforms: TGF-β1, TGF-β2, and TGF-β3. TGF-β is synthesized as a latent form at a high concentration in extracellular matrix and can be activated through many pathways, including thrombospondin and the αvβ6 pathway (
11,
18). The main functions of TGF-β include the inhibition of epithelial proliferation, the induction of gene expression of extracellular matrix genes, and the inhibition of metalloprotease genes (
2,
18). The deletion of TGF-β is lethal and causes widespread tissue inflammation (
12). Overexpression of TGF-β increases endothelial permeability, decreases apical expression of ENaC, and increases apoptosis of alveolar epithelial cells, suggesting that the blockade of TGF-β may be beneficial in acute lung injury. Interestingly, our study has shown that the deletion of β6 or blocking either αvβ6 or TGF-β did not protect against lung injury induced by two different strains of
P. aeruginosa. PA103 is a laboratory strain that secretes the potent virulence factor ExoU, whereas PAK secretes ExoS. There is a possibility that massive damage of the lungs induced by PA103 could have masked a protective effect of αvβ6 inhibition. However, we did not see any protection with the inhibition of αvβ6 when mice were challenged with either bacterial strain, suggesting that the lack of protection from lung injury does not depend on the type of
P. aeruginosa strain.
In summary, inflammation is a necessary component of bacterial killing and, therefore, prevention of inflammation can cripple host defense. Although acute blockade of αvβ6 and TGF-β did not protect the mice from P. aeruginosa-induced lung injury, the lung injury was not significantly increased, nor was bacterial dissemination increased in these short-term or survival experiments. Anti-inflammatory agents should always be tested in experiments in which live bacteria are utilized to determine their effect on host defense.